Allogenicity of Human Cardiac Stem/Progenitor Cells Orchestrated by Programmed Death Ligand 1

Lauden, Laura; Boukouaci, Wahid; Borlado, Luis R.; Lopez, I.; Sepúlveda, Pilar; Tamouza, Ryad; Charron, Dominique; Al-Daccak, Reem

doi:10.1161/circresaha.112.276501

Cited by 71 publications

(117 citation statements)

References 58 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the benefits seen here are consistent with the immunomodulatory properties recently described for CDCs in other experimental settings (57,58). Exogenous cell therapy is under development as an adjunctive strategy to treat ischemic heart disease (59-61).…”

Section: 5supporting

confidence: 85%

See 1 more Smart Citation

Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction

et al. 2015

View full text Add to dashboard Cite

R e s e a R c h a R t i c l e 3 1 4 8jci.org Volume 125 Number 8 August 2015angioplasty to reopen the occluded coronary artery. After flow has been reestablished, the use of adjunctive therapy can be considered without distraction. Adjunctive cell therapy would require thawing of an allogeneic, off-the-shelf product and preparation for administration, which could introduce a delay of up to 20 minutes. Therefore, in our rat model, we subjected rats to 45 minutes of ischemia, followed by 20 minutes of reperfusion. Cells (or vehicle) were then delivered to the coronary circulation ( Figure 1A). To examine whether cell administration could by adoptive transfer of CDC-primed macrophages. Distinctive changes in macrophage gene expression and function underlie the cardioprotective effects of CDCs.

show abstract

Section: 5supporting

confidence: 85%

“…Inflammation is a critical but poorly understood facet of IR injury (2). With evidence supporting an immunomodulatory role for CDCs in vitro (58) and in a chronic model of MI (28, 31), we hypothesized that CDCs would modify the local, innate immune response to confer cardioprotection following IR. and C).…”

Section: 5mentioning

confidence: 99%

Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Oxytocin and specific growth factors governing embryonic cardiogenesis, given in a stage/sequence-specific manner (Figure 13a), produced contractile cardiomyocytes derived from cloned c-kit pos CD45 neg eCSCs, as previously shown 35 . This CardioStem Sphere-beating assay is similar to the protocol used to assess cardiomyocyte differentiation in embryoid bodies 36 .…”

Section: Characterisation Of Ecscssupporting

confidence: 64%

Isolation and characterization of resident endogenous c-Kit+ cardiac stem cells from the adult mouse and rat heart

et al. 2014

View full text Add to dashboard Cite

Article:Smith, AJ orcid.org/0000-0001-7283-5611, Lewis, FC, Aquila, I et al. (6 more authors) (2014) Isolation and characterization of resident endogenous c-Kit cardiac stem cells ⁺ from the adult mouse and rat heart. Nature Protocols, 9 (7). pp. 1662 -1681 . ISSN 1754 -2189 https://doi.org/10.1038/nprot.2014.113 © 2014, Rights Managed by Nature Publishing Group. This is an author produced version of a paper published in Nature Protocols. Uploaded in accordance with the publisher's self-archiving policy.eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/ Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version -refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website. TakedownIf you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. ABSTRACTThis protocol describes the isolation of endogenous c-kit-positive (c-kit pos ), CD45-negative (CD45 neg ) cardiac stem cells (eCSCs), from whole adult mouse and rat hearts. The heart is enzymatically digested via retrograde perfusion of the coronary circulation, resulting in rapid and extensive breakdown of the whole heart. Next the tissue is mechanically dissociated further and cell fractions separated by centrifugation. The c-kit pos CD45 neg eCSC population is isolated by magnetic activated cell sorting technology and purity and cell number assessed by flow cytometry. This process takes approximately 4 hours for mouse eCSCs or 4.5 hours for rat eCSCs. We also describe how to characterise c-kit pos CD45 neg eCSCs. The c-kit pos CD45 neg eCSCs exhibit the defining characteristics of stem cells; being self-renewing, clonogenic and multipotent. This protocol also describes how to differentiate eCSCs into the three main cardiac lineages: functional, beating cardiomyocytes, smooth muscle and endothelial cells. These processes take between 17 and 20 days.

show abstract

“…Conventional strategies such as overexpression of prosurvival genes, such as Akt, β adrenergic stimulation, cotransplanting with others, such as the endothelial cells, modification of the extracellular matrix and immune system are used to enhance survival and retention of CPCs in the heart. [113][114][115][116][117][118][119] Recently, there has been increasing focus on development of novel biomaterials that are coated with stem cells are functionalized with growth, mitotic and chemotactic factors, cytokines, and other biologically active materials. These new biomaterials are biocompatible and biodegradable polymers made of poly (d, l-lactide-co-glycolide acid) or poly(lactic-co-glycolic acid) that allow prolonged and controlled delivery of growth factors in situ and better cell retention in the transplanted area.…”

Section: Novel Delivery Systems For Stem Cell Therapymentioning

confidence: 99%

Recent Developments in Cardiovascular Stem Cells

Madonna

Ferdinándy

Caterina

et al. 2014

Circulation Research

View full text Add to dashboard Cite

45Human embryonic stem cells have been shown to differentiate to beating cardiomyocytes, SA nodal-like cells and mesodermal Recent Developments in Cardiovascular Research:The goal of "Recent Developments" is to provide a concise but comprehensive overview of new advances in cardiovascular research, which we hope will keep our readers abreast of recent scientific discoveries and facilitate discussion, interpretation, and integration of the findings. This will enable readers who are not experts in a particular field to grasp the significance and effect of work performed in other fields. It is our hope and expectation that these "Recent Development" articles will help readers to gain a broader awareness and a deeper understanding of the status of research across the vast landscape of cardiovascular research-The Editors. 50 Moreover, the use of induced pluripotent stem cell-derived cardiac myocytes for cardiac repair is hampered by their immature phenotype and the presence of epigenetic and genetic changes.24,51,52 Resident and bone marrow cells and cortical bone-derived cells are considered as potential sources for differentiation to cardiac myocytes but lacking compelling evidence for cardiac myogenesis and perhaps exerting their salutary biological effects through paracrine mechanisms. 19,29,[53][54][55][56][57][58] Equally exciting and challenging are the discovery and characterization of other CPCs that could give raise to various cardiac cells types, including smooth muscle cells, endothelial cells, and fibroblasts. [59][60][61][62][63] An important problem to overcome is the multiple comorbidities and their comedications of ischemic heart disease patients with heart failure that may affect cytoprotective signaling triggered by the different stem cell, as well as survival and differentiation properties of such stem cells in the injured tissue. [64][65][66] Clearly, the rapid face of discoveries is dazzling and a complete coverage of the recent developments in cardiovascular stem cells would be beyond the scope of this article. We regret that many valuable works were not covered in part or at all included in the present overview on Recent Developments. Clinical Trials In Human PatientsThe ClinicalTrials.gov lists >1000 clinical trials including >600 studies in the United States alone that tests effects of various stem cells in human patients (http://www.clinicaltrials. gov/). The list includes 71 including 38 active clinical trials in patients with heart failure using various stem cells, such as adipose-derived, mesenchymal, human embryonic, autologous CD133 + and CD34 + stem cells among the others.18,67-74Autologous skeletal myoblasts were probably the first cell type used to regenerate functional myocardium. It was tested initially in a rabbit model of myocardial cryoinjury, which showed incorporation of the injected myoblasts and improved myocardial performance. 75 Subsequent observational studies were followed by randomized clinical trials in human patients with heart failure injected with autologous skele...

show abstract

Allogenicity of Human Cardiac Stem/Progenitor Cells Orchestrated by Programmed Death Ligand 1

Cited by 71 publications

References 58 publications

Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction

Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction

Isolation and characterization of resident endogenous c-Kit+ cardiac stem cells from the adult mouse and rat heart

Recent Developments in Cardiovascular Stem Cells

Contact Info

Product

Resources

About